Tarsus Pharmaceuticals (TARS) Share-based Compensation Growth (1y) (2021 - 2026)
Powered by 
Analysis
Tarsus Pharmaceuticals (TARS) Share-based Compensation Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 71.86% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -3.46% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -7.69% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -8.89% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -22.43% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -4.01% |
| 10 | Tarsus Pharmaceuticals | 3.96 Bn | 3.51 Bn | 161.80 Mn | 61.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.41% |
| Mar 31, 2026 | 72.68% |
| Dec 31, 2025 | 93.35% |
| Sep 30, 2025 | 65.11% |
| Jun 30, 2025 | 10.05% |
| Mar 31, 2025 | 25.57% |
| Dec 31, 2024 | 35.04% |
| Sep 30, 2024 | 41.24% |
| Jun 30, 2024 | 44.09% |
| Mar 31, 2024 | 41.30% |
| Dec 31, 2023 | 49.33% |
| Sep 30, 2023 | 46.53% |
| Jun 30, 2023 | 47.00% |
| Mar 31, 2023 | 46.07% |
| Dec 31, 2022 | 68.47% |
| Sep 30, 2022 | 4,677.33% |
| Mar 31, 2022 | -51.33% |
| Dec 31, 2021 | 389.76% |
| Sep 30, 2021 | -97.58% |
| Mar 31, 2021 | 137,250.00% |